Appropriate use criteria for amyloid PET imaging cannot replace guidelines: on behalf of the European Association of Nuclear Medicine(897 views) Booij J, Arbizu J, Darcourt J, Hesse S, Nobili F, Payoux P, Pappata S, Tatsch K, Walker Z, Pagani M
Keywords: Amyloid Beta-Peptides Metabolism, Brain Metabolism Radionuclide Imaging, Humans, Positron-Emission Tomography Methods, Amyloid Beta Protein, Florbetaben, Florbetapir F 18, Flutemetamol F 18, Pittsburgh Compound B, Alzheimer Disease, Brain Perfusion, Cerebrospinal Fluid Analysis, Clinical Practice, Cost Effectiveness Analysis, Dementia, Diffuse Lewy Body Disease, Disease Course, Disease Severity, Dopaminergic System, Early Diagnosis, Food And Drug Administration, Health Care Personnel, Medical Society, Mild Cognitive Impairment, Molecular Imaging, Pathogenesis, Positron Emission Tomography, Practice Guideline, Review, Risk Benefit Analysis, Risk Factor,
Affiliations: *** IBB - CNR ***
Department of Nuclear Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
Nuclear Medicine Department, Clinica Universidad de Navarra, University of Navarra, Pamplona, Spain
Clinical Neurophysiology, Department of Neurosciences, Ophthalmology and Genetics, University of Genoa, Genoa, Italy
INSERM, Toulouse, France
Institute of Biostructure and Bioimaging, CNR, Naples, Italy
Department of Mental Health Sciences Unit, University College London, London, United Kingdom
Institute of Cognitive Sciences and Technologies, CNR, Rome, Italy
References: Not available.
Appropriate use criteria for amyloid PET imaging cannot replace guidelines: on behalf of the European Association of Nuclear Medicine
Not available.
Appropriate use criteria for amyloid PET imaging cannot replace guidelines: on behalf of the European Association of Nuclear Medicine
No results.
Appropriate use criteria for amyloid PET imaging cannot replace guidelines: on behalf of the European Association of Nuclear Medicine